Hdl Handle:
http://hdl.handle.net/10147/207919
Title:
Treatment of Helicobacter pylori infection.
Authors:
O'Connor, Anthony; Gisbert, Javier; O'Morain, Colm
Affiliation:
Department of Gastroenterology, Adelaide and Meath Hospital incorporating the, National Children's Hospital Tallaght, Trinity College Dublin, Dublin, Ireland.
Citation:
Helicobacter. 2009 Sep;14 Suppl 1:46-51.
Journal:
Helicobacter
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207919
DOI:
10.1111/j.1523-5378.2009.00704.x
PubMed ID:
19712168
Abstract:
This article aims to examine current best practice in the field reference to first-line, second-line, rescue and emerging treatment regimens for Helicobacter pylori eradication. The recommended first-line treatment in published guidelines in Europe and North American is proton pump inhibitor combined with amoxicillin and clarithromycin being the favoured regimen. Rates of eradication with this regimen however are falling alarmingly due to a combination of antibiotic resistance and poor compliance with therapy. Bismuth based quadruple therapies and levofloxacin based regimes have been shown to be effective second line regimens. Third-line options include regimes based on rifabutin or furazolidone, but susceptibility testing is the most rational option here, but is currently not used widely enough. Sequential therapy is promising but needs further study and validation outside of Italy. Although the success of first line treatments is falling, if compliance is good and a clear treatment paradigm adhered to, almost universal eradication rates can still be achieved. If compliance is not achievable, the problem of antibiotic resistance will continue to beset any combination of drugs used for H. pylori eradication.
Language:
eng
MeSH:
Anti-Bacterial Agents/*therapeutic use; Clinical Trials as Topic; Drug Resistance, Bacterial; Helicobacter Infections/*drug therapy; Helicobacter pylori/*drug effects/physiology; Humans
ISSN:
1523-5378 (Electronic); 1083-4389 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Connor, Anthonyen_GB
dc.contributor.authorGisbert, Javieren_GB
dc.contributor.authorO'Morain, Colmen_GB
dc.date.accessioned2012-02-01T10:50:06Z-
dc.date.available2012-02-01T10:50:06Z-
dc.date.issued2012-02-01T10:50:06Z-
dc.identifier.citationHelicobacter. 2009 Sep;14 Suppl 1:46-51.en_GB
dc.identifier.issn1523-5378 (Electronic)en_GB
dc.identifier.issn1083-4389 (Linking)en_GB
dc.identifier.pmid19712168en_GB
dc.identifier.doi10.1111/j.1523-5378.2009.00704.xen_GB
dc.identifier.urihttp://hdl.handle.net/10147/207919-
dc.description.abstractThis article aims to examine current best practice in the field reference to first-line, second-line, rescue and emerging treatment regimens for Helicobacter pylori eradication. The recommended first-line treatment in published guidelines in Europe and North American is proton pump inhibitor combined with amoxicillin and clarithromycin being the favoured regimen. Rates of eradication with this regimen however are falling alarmingly due to a combination of antibiotic resistance and poor compliance with therapy. Bismuth based quadruple therapies and levofloxacin based regimes have been shown to be effective second line regimens. Third-line options include regimes based on rifabutin or furazolidone, but susceptibility testing is the most rational option here, but is currently not used widely enough. Sequential therapy is promising but needs further study and validation outside of Italy. Although the success of first line treatments is falling, if compliance is good and a clear treatment paradigm adhered to, almost universal eradication rates can still be achieved. If compliance is not achievable, the problem of antibiotic resistance will continue to beset any combination of drugs used for H. pylori eradication.en_GB
dc.language.isoengen_GB
dc.subject.meshAnti-Bacterial Agents/*therapeutic useen_GB
dc.subject.meshClinical Trials as Topicen_GB
dc.subject.meshDrug Resistance, Bacterialen_GB
dc.subject.meshHelicobacter Infections/*drug therapyen_GB
dc.subject.meshHelicobacter pylori/*drug effects/physiologyen_GB
dc.subject.meshHumansen_GB
dc.titleTreatment of Helicobacter pylori infection.en_GB
dc.contributor.departmentDepartment of Gastroenterology, Adelaide and Meath Hospital incorporating the, National Children's Hospital Tallaght, Trinity College Dublin, Dublin, Ireland.en_GB
dc.identifier.journalHelicobacteren_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.